{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:37:58Z","timestamp":1793813878275,"version":"4.6.1"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118262","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:29:22Z","timestamp":1784179762000},"page":"118262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Core genes drive treatment resistance in triple-negative breast cancer: characteristics, mechanisms, intervention strategies"],"prefix":"10.1016","volume":"252","author":[{"given":"Zi-Xu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-Lei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0005","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118262_b0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.breast.2022.08.012","article-title":"A systematic review and meta-analysis of BRCA1\/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer","volume":"66","author":"Jia","year":"2022","journal-title":"Breast"},{"issue":"52","key":"10.1016\/j.bcp.2026.118262_b0015","doi-asserted-by":"crossref","first-page":"40910","DOI":"10.1074\/jbc.C000607200","article-title":"Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain","volume":"275","author":"Hu","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010348","article-title":"Homologous recombination deficiencies and hereditary tumors","volume":"23","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118262_b0025","article-title":"Effects of neoadjuvant chemotherapy in ovarian cancer patients with different germline BRCA1\/2 mutational status: a retrospective cohort study","volume":"11","author":"Fu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118262_b0030","doi-asserted-by":"crossref","unstructured":"Singh, D.D., A. Parveen, and D.K. Yadav, Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. Biomedicines, 2021. 9(11).","DOI":"10.3390\/biomedicines9111512"},{"issue":"9","key":"10.1016\/j.bcp.2026.118262_b0035","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-17-0098","article-title":"Modeling therapy resistance in BRCA1\/2-mutant cancers","volume":"16","author":"Dr\u00e9an","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118262_b0040","article-title":"Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy","volume":"272","author":"Mokhtar","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.bcp.2026.118262_b0045","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1074\/jbc.M116.755884","article-title":"Structures of the multidrug transporter p-glycoprotein reveal asymmetric atp binding and the mechanism of polyspecificity","volume":"292","author":"Esser","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118262_b0050","doi-asserted-by":"crossref","first-page":"E1973","DOI":"10.1073\/pnas.1717044115","article-title":"Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1","volume":"115","author":"Alam","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010362","article-title":"Structure-function relationships in the human p-glycoprotein (ABCB1): insights from molecular dynamics simulations","volume":"23","author":"Mora Lagares","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118262_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044140","article-title":"Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia","volume":"24","author":"Labbozzetta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118262_b0065","doi-asserted-by":"crossref","first-page":"0095","DOI":"10.34133\/bmr.0095","article-title":"Targeting miR-21 to Overcome P-glycoprotein Drug Efflux in doxorubicin-resistant 4T1 breast cancer","volume":"28","author":"Kim","year":"2024","journal-title":"Biomater Res"},{"issue":"6","key":"10.1016\/j.bcp.2026.118262_b0070","article-title":"Multidrug resistance of cancer cells and the vital role of P-glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life (basel)"},{"issue":"12","key":"10.1016\/j.bcp.2026.118262_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122703","article-title":"Enhancing paclitaxel efficacy with piperine-paclitaxel albumin nanoparticles in multidrug-resistant triple-negative breast cancer by inhibiting P-glycoprotein","volume":"15","author":"Xu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2026.118262_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102602","article-title":"Aurintricarboxylic acid, an inhibitor of cystathionine \u03b3-lyase, enhances the sensitivity of chemotherapy drugs in TNBC","volume":"63","author":"Han","year":"2026","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bcp.2026.118262_b0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cancergen.2024.10.005","article-title":"Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies","author":"Liu","year":"2024","journal-title":"Cancer Genet."},{"key":"10.1016\/j.bcp.2026.118262_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2022.146930","article-title":"Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer","volume":"850","author":"Kumar","year":"2023","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0095","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/s41598-025-87286-z","article-title":"Mechanistic insights into pachymic acid's action on triple-negative breast Cancer through TOP2A targeting","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118262_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118041","article-title":"Novel \u03b2-carboline derivatives show promise as dual-target inhibitors of DNA and TOP2A for the treatment of triple negative breast cancer","volume":"298","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118262_b0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.chembiol.2016.03.017","article-title":"GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity","volume":"23","author":"Louie","year":"2016","journal-title":"Cell Chem. Biol."},{"issue":"52","key":"10.1016\/j.bcp.2026.118262_b0110","doi-asserted-by":"crossref","first-page":"30866","DOI":"10.1074\/jbc.M115.656140","article-title":"Phosphorylation of glutathione S-transferase P1 (GSTP1) by epidermal growth factor receptor (EGFR) promotes formation of the GSTP1-c-Jun N-terminal kinase (JNK) complex and suppresses JNK downstream signaling and apoptosis in brain tumor cells","volume":"290","author":"Okamura","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118262_b0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.freeradbiomed.2011.04.013","article-title":"The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer","volume":"51","author":"Tew","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0120","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-017-0627-9","article-title":"CLDN6 promotes chemoresistance through GSTP1 in human breast cancer","volume":"36","author":"Yang","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118262_b0125","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1039\/C6MB00250A","article-title":"A tyrosine-reactive irreversible inhibitor for glutathione S-transferase Pi (GSTP1)","volume":"12","author":"Crawford","year":"2016","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.bcp.2026.118262_b0130","doi-asserted-by":"crossref","unstructured":"Afreen Begum Abdul, Q., A. Syed Ayaz, and M. Santosh Namdeo, Design and Synthesis of (2,3-dichloro-4-(3-(substituted Phenyl)acryloyl) phenoxy) Substituted Carboxylic Acid as Potent Glutathione-s-transferase Inhibitors, Anti-breast-cancer Agents and Enhancing Therapeutic Efficacy of Anticancer Agents. Med Chem, 2025. 21(4).","DOI":"10.2174\/0115734064316508240911032442"},{"key":"10.1016\/j.bcp.2026.118262_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1226181","article-title":"TUBB3 and KIF21A in neurodevelopment and disease","volume":"17","author":"Puri","year":"2023","journal-title":"Front. Neurosci."},{"issue":"16","key":"10.1016\/j.bcp.2026.118262_b0140","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.febslet.2008.06.013","article-title":"The paclitaxel site in tubulin probed by site-directed mutagenesis of Saccharomyces cerevisiae beta-tubulin","volume":"582","author":"Entwistle","year":"2008","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.bcp.2026.118262_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70203","article-title":"RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic\u2013nuclear shuttling in human triple\u2010negative breast cancer","volume":"15","author":"Huang","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.20517\/cdr.2022.96","article-title":"Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance","volume":"6","author":"Scherbakov","year":"2023","journal-title":"Cancer Drug Resist"},{"issue":"558","key":"10.1016\/j.bcp.2026.118262_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2879","article-title":"BET inhibition increases \u03b2III-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine","volume":"12","author":"Kanojia","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118262_b0160","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1021\/np000629f","article-title":"New natural epothilones from Sorangium cellulosum, strains so ce90\/B2 and so ce90\/D13: isolation, structure elucidation, and SAR studies","volume":"64","author":"Hardt","year":"2001","journal-title":"J. Nat. Prod."},{"issue":"18","key":"10.1016\/j.bcp.2026.118262_b0165","first-page":"6026","article-title":"Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest","volume":"63","author":"Kamath","year":"2003","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118262_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076063","article-title":"Epothilones as Natural Compounds for Novel Anticancer Drugs Development","volume":"24","author":"Villegas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118262_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2025.106961","article-title":"Identification of presenilin mutations that have sufficient gamma-secretase proteolytic activity to mediate Notch signaling but disrupt organelle and neuronal health","volume":"212","author":"Ashkavand","year":"2025","journal-title":"Neurobiol. Dis."},{"issue":"18","key":"10.1016\/j.bcp.2026.118262_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168218","article-title":"Permissive conformations of a transmembrane helix allow intramembrane proteolysis by \u03b3-secretase","volume":"435","author":"Ortner","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118262_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116577","article-title":"Activation of the \u03b3-secretase\/NICD-PXR\/Notch pathway induces Taxol resistance in triple-negative breast cancer","volume":"230","author":"Wang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118262_b0190","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.bpj.2017.10.012","article-title":"Allosteric modulation of intact \u03b3-secretase structural dynamics","volume":"113","author":"Lee","year":"2017","journal-title":"Biophys. J ."},{"key":"10.1016\/j.bcp.2026.118262_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.theriogenology.2025.117710","article-title":"Presenilin-1 is present in boar spermatozoa and regulates acrosome reaction in the absence of glucose","volume":"251","author":"Mart\u00edn-Hidalgo","year":"2026","journal-title":"Theriogenology"},{"issue":"17","key":"10.1016\/j.bcp.2026.118262_b0200","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1074\/jbc.RA119.007671","article-title":"A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting \u03b3-secretase\u2013mediated activation of Notch signaling","volume":"294","author":"Das","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118262_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26052303","article-title":"CRISPR\/Cas9 targeting of aldehyde dehydrogenase 1A1 reveals heterogeneous roles in radiation response and redox stress across clonal lines in triple-negative breast cancer","volume":"26","author":"Ajayi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010251","article-title":"The significance of aldehyde dehydrogenase 1 in cancers","volume":"26","author":"Nguyen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118262_b0215","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/his.14129","article-title":"The prognostic significance of ALDH1A1 expression in early invasive breast cancer","volume":"77","author":"Althobiti","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.bcp.2026.118262_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110120","article-title":"Aldehyde dehydrogenase 1A1 and 1A3 isoforms \u2013 mechanism of activation and regulation in cancer","volume":"87","author":"Poturnajova","year":"2021","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.bcp.2026.118262_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102039","article-title":"Differential functional roles of ALDH1A1 and ALDH1A3 in mediating metastatic behavior and therapy resistance of human breast cancer cells","volume":"18","author":"Croker","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1878-0261.13528","article-title":"ALDH1A3 promotes invasion and metastasis in triple-negative breast cancer by regulating the plasminogen activation pathway","volume":"18","author":"Bharadwaj","year":"2024","journal-title":"Mol. Oncol."},{"issue":"21","key":"10.1016\/j.bcp.2026.118262_b0235","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","article-title":"Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118262_b0240","doi-asserted-by":"crossref","unstructured":"MacLean, M.R., B.L. Bernardoni, W. Fernando, G. Petrarolo, I. D\u2019Agostino, C.A. Dean, et al., Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs. iScience, 2026.","DOI":"10.1016\/j.isci.2026.114863"},{"issue":"4","key":"10.1016\/j.bcp.2026.118262_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041396","article-title":"Divide and conquer-targeted therapy for triple-negative breast cancer","volume":"26","author":"Nedeljkovi\u0107","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.bcp.2026.118262_b0250","article-title":"Countering triple negative breast cancer via impeding Wnt\/\u03b2-catenin signaling, a phytotherapeutic approach","volume":"11","author":"Arzi","year":"2022","journal-title":"Plants (basel)"},{"key":"10.1016\/j.bcp.2026.118262_b0255","article-title":"Molecular mechanisms and signaling pathways related to brain metastasis in breast cancer","volume":"16","author":"Liang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118262_b0260","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118262_b0265","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74218","article-title":"Structure of the human ATM kinase and mechanism of Nbs1 binding","volume":"11","author":"Warren","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2026.118262_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102351","article-title":"Mechanisms of radioresistance and radiosensitization strategies for Triple negative Breast Cancer","volume":"55","author":"Wang","year":"2025","journal-title":"Transl. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118262_b0275","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41419-021-04405-0","article-title":"MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance","volume":"12","author":"Mehlich","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118262_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104811","article-title":"Targeting the DNA damage response to enhance radiotherapy in soft tissue sarcomas","volume":"214","author":"van Riet","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bcp.2026.118262_b0285","doi-asserted-by":"crossref","unstructured":"Gurung, D., J.A. Danielson, A. Tasnim, J.T. Zhang, Y. Zou, and J.Y. Liu, Proline Isomerization: From the Chemistry and Biology to Therapeutic Opportunities. Biology (Basel), 2023. 12(7).","DOI":"10.3390\/biology12071008"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0290","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1007\/s12672-025-03844-x","article-title":"Dual inhibition of ATR and PARP reverses acquired PARP inhibitor resistance in triple negative breast cancer","volume":"16","author":"Guney Eskiler","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bcp.2026.118262_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118137","article-title":"ATM inhibitors in cancer radiotherapy: Mechanisms, clinical development, and future directions","volume":"300","author":"Al-Zoubi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118262_b0300","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118262_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115877","article-title":"Targeting the DNA repair pathway for breast cancer therapy: beyond the molecular subtypes","volume":"169","author":"Qu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118262_b0310","doi-asserted-by":"crossref","first-page":"43517","DOI":"10.1038\/srep43517","article-title":"WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance","volume":"7","author":"Zheng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118262_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113797","article-title":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","volume":"155","author":"Ahmed","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118262_b0320","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.dnarep.2015.04.030","article-title":"Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment","volume":"32","author":"Scanlon","year":"2015","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bcp.2026.118262_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2024.100185","article-title":"Functions and inhibitors of CHK1 in cancer therapy","volume":"22","author":"Jiang","year":"2024","journal-title":"Med. Drug Discovery"},{"issue":"3","key":"10.1016\/j.bcp.2026.118262_b0330","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118262_b0335","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/ml200249h","article-title":"Discovery of a novel series of CHK1 kinase inhibitors with a distinctive hinge binding mode","volume":"3","author":"Huang","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bcp.2026.118262_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107513","article-title":"In-depth mapping of DNA-PKcs signaling uncovers noncanonical features of its kinase specificity","volume":"300","author":"Marshall","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0345","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bcp.2026.118262_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/cells14100748","article-title":"Cancer vulnerabilities through targeting the ATR\/Chk1 and ATM\/Chk2 axes in the context of DNA damage","volume":"14","author":"Fernandez","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010077","article-title":"Molecular basis of oncogenic PI3K proteins","volume":"17","author":"Sheng","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2026.118262_b0360","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118262_b0365","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21037\/atm-21-698","article-title":"PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway","volume":"9","author":"Hu","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"318","key":"10.1016\/j.bcp.2026.118262_b0370","doi-asserted-by":"crossref","first-page":"ra29","DOI":"10.1126\/scisignal.2005125","article-title":"Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-akt pathway in triple-negative breast cancer","volume":"7","author":"Tao","year":"2014","journal-title":"Sci. Signal."},{"issue":"34","key":"10.1016\/j.bcp.2026.118262_b0375","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304071120","article-title":"Structural insights into the interaction of three Y-shaped ligands with PI3K\u03b1","volume":"120","author":"Zhou","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118262_b0380","doi-asserted-by":"crossref","unstructured":"Oliveira, F.P.d., M.L. Nogueira, A.F.C. Galv\u00e3o, R.B. Dias, and D.P. Bezerra, Translational drugs targeting cancer stem cells in triple-negative breast cancer. Molecular Therapy Oncology, 2025. 33(3).","DOI":"10.1016\/j.omton.2025.201008"},{"issue":"4","key":"10.1016\/j.bcp.2026.118262_b0385","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s13205-024-03955-2","article-title":"Ab initio modeling of human IRS1 protein to find novel target to dock with drug MH to mitigate T2DM diabetes by insulin signaling","volume":"14","author":"Singh","year":"2024","journal-title":"3 Biotech"},{"key":"10.1016\/j.bcp.2026.118262_b0390","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12885-015-1249-2","article-title":"Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors","volume":"15","author":"Urtasun","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118262_b0395","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.htct.2024.02.017","article-title":"NT157 exhibits antineoplastic effects by targeting IRS and STAT3\/5 signaling in multiple myeloma","volume":"46","author":"de Queiroz","year":"2024","journal-title":"Hematol. Transfusion Cell Therapy"},{"issue":"4","key":"10.1016\/j.bcp.2026.118262_b0400","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/mco2.97","article-title":"CDK4\/6 inhibitors: a potential therapeutic approach for triple negative breast cancer","volume":"2","author":"Saleh","year":"2021","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0405","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-023-01615-6","article-title":"Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer","volume":"25","author":"Mani","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2026.118262_b0410","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.omtn.2018.11.019","article-title":"The modulatory role of MicroRNA-873 in the progression of KRAS-driven cancers","volume":"14","author":"Mokhlis","year":"2019","journal-title":"Mol. Therapy Nucleic Acids"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0415","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-025-01066-z","article-title":"Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair","volume":"31","author":"Kim","year":"2025","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2026.118262_b0420","article-title":"PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway?","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0425","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0430","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118262_b0435","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154402","article-title":"RB expression confers sensitivity to CDK4\/6 inhibitor-mediated radiosensitization across breast cancer subtypes","volume":"7","author":"Pesch","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2026.118262_b0440","article-title":"Breast Cancer Resistance to Cyclin-Dependent Kinases 4\/6 Inhibitors: Intricacy of the Molecular Mechanisms","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118262_b0445","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122253","article-title":"Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases significantly Sensitizes Triple-negative Breast Cancer to CDK4\/6 Inhibition","volume":"16","author":"Demirsoy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-023-00475-1","article-title":"CDK4\/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer","volume":"12","author":"Shrestha","year":"2023","journal-title":"Oncogenesis"},{"issue":"3","key":"10.1016\/j.bcp.2026.118262_b0455","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10549-023-06878-3","article-title":"Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs","volume":"198","author":"Guillen","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.bcp.2026.118262_b0460","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26051488","article-title":"Development of CDK4\/6 Inhibitors: a five Years Update","volume":"26","author":"Ammazzalorso","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118262_b0465","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740002","article-title":"Palbociclib Induces senescence in melanoma and breast cancer cells and leads to additive growth arrest in combination with irradiation","volume":"11","author":"Jost","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118262_b0470","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202413103","article-title":"Dual inhibition of CDK4\/6 and CDK7 suppresses triple\u2010negative breast cancer progression via epigenetic modulation of SREBP1\u2010regulated cholesterol metabolism","volume":"12","author":"Yang","year":"2024","journal-title":"Adv. Sci."},{"issue":"20","key":"10.1016\/j.bcp.2026.118262_b0475","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188839","article-title":"Dual targeting of CDK4\/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models","volume":"135","author":"Kim","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0480","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35059-x","article-title":"EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis","volume":"13","author":"Verma","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2026.118262_b0485","article-title":"DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice","volume":"11","author":"Chai","year":"2024","journal-title":"Genes Dis"},{"issue":"9","key":"10.1016\/j.bcp.2026.118262_b0490","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005068","article-title":"Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy","volume":"10","author":"Yang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118262_b0495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031078","article-title":"Pharmacological inhibition of MDM2 induces apoptosis in p53-mutated triple-negative breast cancer","volume":"26","author":"On","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118262_b0500","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bcp.2026.118262_b0505","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41418-025-01549-w","article-title":"The roles of mutant p53 in reprogramming and inflammation in breast cancers","volume":"32","author":"Kummar","year":"2025","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.bcp.2026.118262_b0510","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00262-022-03343-w","article-title":"CXCL9 influences the tumor immune microenvironment by stimulating JAK\/STAT pathway in triple-negative breast cancer","volume":"72","author":"Wu","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0515","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13205-024-04195-0","article-title":"Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications","volume":"15","author":"Priya","year":"2025","journal-title":"3 Biotech"},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0520","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5450","article-title":"Mechanism of exosomes in the tumor microenvironment in the abscopal effect (Review)","volume":"62","author":"Kuang","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118262_b0525","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010523","article-title":"ATM: functions of ATM kinase and its relevance to hereditary tumors","volume":"23","author":"Ueno","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1731","key":"10.1016\/j.bcp.2026.118262_b0530","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0283","article-title":"ATM-dependent pathways of chromatin remodelling and oxidative DNA damage responses","volume":"372","author":"Berger","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.bcp.2026.118262_b0535","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-genet-021920-092410","article-title":"RAD51 gene family structure and function","volume":"54","author":"Bonilla","year":"2020","journal-title":"Annu. Rev. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2026.118262_b0540","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1038\/mtna.2016.82","article-title":"Notch-1 confers chemoresistance in lung adenocarcinoma to taxanes through AP-1\/microRNA-451 mediated regulation of MDR-1","volume":"5","author":"Huang","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"12","key":"10.1016\/j.bcp.2026.118262_b0545","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1172\/JCI76611","article-title":"NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells","volume":"124","author":"Zhao","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118262_b0550","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.32893","article-title":"IRS-1 acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling","volume":"7","author":"Yoneyama","year":"2018","journal-title":"Elife"},{"issue":"13","key":"10.1016\/j.bcp.2026.118262_b0555","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.7150\/jca.77619","article-title":"Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer","volume":"13","author":"Quan","year":"2022","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118262_b0560","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:17:18Z","timestamp":1786652238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":112,"alternative-id":["S0006295226006015"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118262","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Core genes drive treatment resistance in triple-negative breast cancer: characteristics, mechanisms, intervention strategies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118262"}}